A recent study from Brown University has highlighted a possible connection between the shingles vaccine and a lower risk of dementia in older adults. This research, which appears in The Annals of Internal Medicine, looked at over 509,926 U.S. adults aged 66 and older who were admitted to skilled nursing facilities.
The study found that individuals who received at least one dose of the Shingrix vaccine saw a 24% reduction in their risk of developing dementia over four years compared to those who did not get vaccinated. However, the researchers emphasized that these findings show an association but do not confirm that the vaccine directly prevents dementia.
Dr. Ajeet Sodhi, a neurologist in Orlando, Florida, acknowledged the significance of these findings, stating that they add to a growing body of research suggesting a link between shingles vaccination and slower cognitive decline. He noted that this could be the third or fourth study reaching similar conclusions, indicating that vaccination might help delay the onset of dementia.
Researchers speculate that the vaccine may help prevent shingles and its complications, which can lead to conditions like vascular dementia due to the virus’s association with strokes. Dr. Sodhi also remarked on recent research supporting cardiovascular benefits from shingles vaccination, noting a significant decrease in occurrences of heart disease and strokes linked to the vaccine.
While the data is compelling, Dr. Sodhi pointed out that the shingles vaccine is not currently recognized as a direct treatment for cognitive decline. He stated that while the correlation is strong, it doesn’t establish a definitive cause-and-effect relationship.
It’s worth noting the primary purpose of the FDA-approved Shingrix vaccine is to prevent shingles, a painful condition resulting from the reactivation of the varicella-zoster virus, which also causes chickenpox. The vaccine is especially important for preventing severe nerve pain and complications related to shingles, like post-herpetic neuralgia, which can cause long-lasting discomfort even after the rash has healed.
The Centers for Disease Control and Prevention recommends the Shingrix vaccine for adults aged 50 and older and those 19 and older who are immunocompromised. It’s important to recognize that while the vaccine reduces the risk of shingles and its associated complications, it is not intended to prevent or treat dementia.
As concerns about memory loss increase, experts urge individuals to consult their doctors if they notice any troubling signs. Dr. Sodhi emphasizes the importance of early evaluation, as the sooner one seeks help, the better the chances of effective treatment.
